Published in Oncoimmunology on December 21, 2014
Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | NCT01968109
IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma | NCT00349934
Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies | NCT02061761
Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides | NCT00365937
Phase I Study of IMP321 Given Alone or as an Adjuvant to a Reference Flu Antigen | NCT00354263
LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma. Oncoimmunology (2016) 0.75
Amelanotic Melanoma Presenting with Plasmacytoid Morphology and BRAF V600 Mutation. Rare Tumors (2015) 0.75
Plasmacytoid dendritic cells: recent progress and open questions. Annu Rev Immunol (2011) 3.32
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A (2010) 3.12
Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med (2013) 2.39
Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer (2011) 1.53
LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites. J Immunol (2010) 1.37
The pathogenic role of tissue-resident immune cells in psoriasis. Trends Immunol (2007) 1.27
Targeting uptake receptors on human plasmacytoid dendritic cells triggers antigen cross-presentation and robust type I IFN secretion. J Immunol (2013) 1.09
Anticancer TLR agonists on the ropes. Nat Rev Drug Discov (2012) 1.05
Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity. Cancer Res (2006) 0.95
Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: involvement of LAG-3. J Invest Dermatol (2014) 0.91